# Phase I Study GX-G3 in Healthy Subjects

> **NCT01951027** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GX-G3 12.5 μg/kg or Placebo
- **DRUG:** GX-G3 25 μg/kg or Placebo
- **DRUG:** GX-G3 50 μg/kg or Placebo
- **DRUG:** GX-G3 100 μg/kg or Placebo

## Key facts

- **NCT ID:** NCT01951027
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2015-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951027, "Phase I Study GX-G3 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01951027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*